80
Views
6
CrossRef citations to date
0
Altmetric
Original Research

Using a multidimensional unfolding approach to assess multiple sclerosis patient preferences for disease-modifying therapy: a pilot study

, , , , &
Pages 995-999 | Published online: 29 May 2017

References

  • CompstonAColesAMultiple sclerosisLancet200837296481502151718970977
  • TorkildsenOMyhrKMBoLDisease-modifying treatments for multiple sclerosis-a review of approved medicationsEur J Neurol201623suppl 1182726563094
  • SempereAPGimenez-MartinezJSafety considerations when choosing the appropriate treatment for patients with multiple sclerosisExpert Opin Drug Saf201413101287128925164167
  • GafsonACranerMJMattthewsPMPersonalised medicine for multiple sclerosis careMult Scler201723336236927672137
  • ColliganEMetzlerATiryakiEShared decision-making in multiple sclerosis: a reviewMult Scler201723218519027663871
  • RyanMScottDAReevesCEliciting public preferences for healthcare: a systematic review of techniquesHealth Technol Assess2001551186
  • FriedTRShared decision making-finding the sweet spotN Engl J Med2016374210410626760081
  • BridgesHPHuberABMarshallDConjoint analysis applications in health: a checklist of the ISPOR good research practices for conjoint analysis task forceValue Health201114440341321669364
  • De LeeuwJMultidimensional unfoldingEverittBSHowellDCEncyclopedia of Statistics in Behavioral ScienceNew YorkWiley200512891294
  • ZaborskiAGeometrical presentation of preferences by using unfolding modelsActa Universitatis Lodziensis Folia Oeconomica2010235365373
  • De SarboWSKimSA review of the major multidimensional scaling models for the analysis of preference-dominance data in marketingMouthinhoLHuarngKQuantitative Modelling in Marketing and ManagementLondonWorld Scientific Press2013325
  • PolmanCHReingoldSCBanwellBDiagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteriaAnn Neurol201169229230221387374
  • KurtzkeJFRating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS)Neurology19833311144414526685237
  • BadiaXRosetMMonserratSHerdmanMSeguraAThe Spanish version of EuroQoL: a description and its applicationsMed Clin (Barcelona)1999112suppl 17985
  • De las CuevasCPerestelo-PerezLRivero-SantanaACebolla-MartíASchollIHärterMValidation of the Spanish version of the 9-item Shared Decision-Making QuestionnaireHealth Expect20151862143215324593044
  • WilsonLLoucksABuiCPatient-centered decision making: use of conjoint analysis to determine risk-benefit trade-offs for preference sensitive treatment choicesJ Neurol Sci20143441–2808725037284
  • BusingFMTAGroenenPJFHeiserWJAvoiding degeneracy in multidimensional unfolding by penalizing on the coefficient of variationPsychometrika20057014976
  • SoundyARoskellCAdamsRUnderstanding health care professional-patient interactions in multiple sclerosis: a systematic review and thematic synthesisOpen J Ther Rehabil20164187217
  • HeesenCSolariAGiordanoAKasperJKöpkeSDecisions on multiple sclerosis immunotherapy: new treatment complexities urge patient engagementJ Neurol Sci20113061–219219720920815
  • LoreficeLMuraGConiGWhat do multiple sclerosis patients and their caregivers perceive as unmet needs?BMC Neurol20131317724237586
  • JohnsonFRVan HoutvenGOzdemirSHassSWhiteJMillerDWMultiple sclerosis patients’ benefit-risk preferences: serious adverse events risks versus treatment efficacyJ Neurol2009256455456219444531
  • PoulosCKinterEYangJCBridgesJFPosnerJRederATPatient preferences for injectable treatments for multiple sclerosis in the United States: a Discrete-choice experimentPatient20169217118026259849
  • PoulosCKinterEYangJCA discrete-choice experiment to determine patient preferences for injectable multiple sclerosis treatments in GermanyTher Adv Neurol Disord2016929510427006697
  • WilsonLLoucksAGipsonGPatient preferences for attributes of multiple sclerosis disease-modifying therapies development and results of a ratings-based conjoint analysisInt J MS Care2015172748225892977
  • LyndLDTraboulseeAMarraCAQuantitative analysis of multiple sclerosis patients’ preferences for drug treatments: a best-worst scaling studyTher Adv Neurol Disord20169428729627366235
  • TurCTintoréMVidal-JordanaÁRisk acceptance in multiple sclerosis patients on natalizumab treatmentPLoS One2013812e8279624340060